Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

A Specific Probe Substrate for Evaluation of CYP4A11 Activity in Human Tissue Microsomes and a Highly Selective CYP4A11 Inhibitor: Luciferin-4A and Epalrestat.

Yamaori S, Araki N, Shionoiri M, Ikehata K, Kamijo S, Ohmori S, Watanabe K.

J Pharmacol Exp Ther. 2018 Jul 5. pii: jpet.118.249557. doi: 10.1124/jpet.118.249557. [Epub ahead of print]

2.

Lack of epithelial PPARγ causes cystic adenomatoid malformations in mouse fetal lung.

Kim JH, Yamaori S, Tanabe T, Takagi M, Matsubara T, Okamoto M, Kimura S, Gonzalez FJ.

Biochem Biophys Res Commun. 2017 Sep 16;491(2):271-276. doi: 10.1016/j.bbrc.2017.07.113. Epub 2017 Jul 21.

PMID:
28739257
3.

Systemic QX-314 Reduces Bone Cancer Pain through Selective Inhibition of Transient Receptor Potential Vanilloid Subfamily 1-expressing Primary Afferents in Mice.

Fuseya S, Yamamoto K, Minemura H, Yamaori S, Kawamata T, Kawamata M.

Anesthesiology. 2016 Jul;125(1):204-18. doi: 10.1097/ALN.0000000000001152.

PMID:
27176211
4.

Cannabidiol induces expression of human cytochrome P450 1A1 that is possibly mediated through aryl hydrocarbon receptor signaling in HepG2 cells.

Yamaori S, Kinugasa Y, Jiang R, Takeda S, Yamamoto I, Watanabe K.

Life Sci. 2015 Sep 1;136:87-93. doi: 10.1016/j.lfs.2015.07.007. Epub 2015 Jul 15.

PMID:
26187180
5.

In vitro inhibition of CYP2C9-mediated warfarin 7-hydroxylation by iguratimod: possible mechanism of iguratimod-warfarin interaction.

Yamaori S, Takami K, Shiozawa A, Sakuyama K, Matsuzawa N, Ohmori S.

Biol Pharm Bull. 2015;38(3):441-7. doi: 10.1248/bpb.b14-00711. Epub 2015 Jan 19.

6.

Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol.

Yamaori S, Okushima Y, Yamamoto I, Watanabe K.

Chem Biol Interact. 2014 May 25;215:62-8. doi: 10.1016/j.cbi.2014.03.007. Epub 2014 Mar 22.

PMID:
24667653
7.

Δ-Tetrahydrocannabinol induces cytotoxicity in macrophage J774-1 cells: involvement of cannabinoid receptor 2 and p38 MAPK.

Yamaori S, Ishii H, Chiba K, Yamamoto I, Watanabe K.

Toxicology. 2013 Dec 15;314(2-3):254-61. doi: 10.1016/j.tox.2013.10.007. Epub 2013 Oct 30.

PMID:
24184660
8.

Structural requirements for potent direct inhibition of human cytochrome P450 1A1 by cannabidiol: role of pentylresorcinol moiety.

Yamaori S, Okushima Y, Masuda K, Kushihara M, Katsu T, Narimatsu S, Yamamoto I, Watanabe K.

Biol Pharm Bull. 2013;36(7):1197-203.

9.

Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19.

Jiang R, Yamaori S, Okamoto Y, Yamamoto I, Watanabe K.

Drug Metab Pharmacokinet. 2013;28(4):332-8. Epub 2013 Jan 15.

10.

Differentiation of monkey embryonic stem cells to hepatocytes by feeder-free dispersion culture and expression analyses of cytochrome p450 enzymes responsible for drug metabolism.

Maruyama J, Matsunaga T, Yamaori S, Sakamoto S, Kamada N, Nakamura K, Kikuchi S, Ohmori S.

Biol Pharm Bull. 2013;36(2):292-8. Epub 2012 Dec 8.

11.

Implication of intestinal VDR deficiency in inflammatory bowel disease.

Kim JH, Yamaori S, Tanabe T, Johnson CH, Krausz KW, Kato S, Gonzalez FJ.

Biochim Biophys Acta. 2013 Jan;1830(1):2118-28. doi: 10.1016/j.bbagen.2012.09.020. Epub 2012 Oct 2.

12.

Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity.

Yamaori S, Koeda K, Kushihara M, Hada Y, Yamamoto I, Watanabe K.

Drug Metab Pharmacokinet. 2012;27(3):294-300. Epub 2011 Dec 13.

13.

Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6.

Yamaori S, Okamoto Y, Yamamoto I, Watanabe K.

Drug Metab Dispos. 2011 Nov;39(11):2049-56. doi: 10.1124/dmd.111.041384. Epub 2011 Aug 5.

14.

Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes.

Jiang R, Yamaori S, Takeda S, Yamamoto I, Watanabe K.

Life Sci. 2011 Aug 1;89(5-6):165-70. doi: 10.1016/j.lfs.2011.05.018. Epub 2011 Jun 16.

PMID:
21704641
15.

Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety.

Yamaori S, Ebisawa J, Okushima Y, Yamamoto I, Watanabe K.

Life Sci. 2011 Apr 11;88(15-16):730-6. doi: 10.1016/j.lfs.2011.02.017. Epub 2011 Feb 26.

PMID:
21356216
16.

Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes.

Yamaori S, Kushihara M, Yamamoto I, Watanabe K.

Biochem Pharmacol. 2010 Jun 1;79(11):1691-8. doi: 10.1016/j.bcp.2010.01.028. Epub 2010 Feb 1.

PMID:
20117100
17.

Delta(9)-Tetrahydrocannabinol enhances MCF-7 cell proliferation via cannabinoid receptor-independent signaling.

Takeda S, Yamaori S, Motoya E, Matsunaga T, Kimura T, Yamamoto I, Watanabe K.

Toxicology. 2008 Mar 12;245(1-2):141-6. doi: 10.1016/j.tox.2007.12.019. Epub 2007 Dec 28.

PMID:
18249480
18.

Nafamostat is hydrolysed by human liver cytosolic long-chain acyl-CoA hydrolase.

Yamaori S, Ukena E, Fujiyama N, Funahashi T, Kimura T, Yamamoto I, Ohshima T, Matsumura K, Oda M, Watanabe K.

Xenobiotica. 2007 Mar;37(3):260-70.

PMID:
17624024
19.

Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes.

Watanabe K, Yamaori S, Funahashi T, Kimura T, Yamamoto I.

Life Sci. 2007 Mar 20;80(15):1415-9. Epub 2007 Jan 17.

PMID:
17303175
20.

Involvement of human blood arylesterases and liver microsomal carboxylesterases in nafamostat hydrolysis.

Yamaori S, Fujiyama N, Kushihara M, Funahashi T, Kimura T, Yamamoto I, Sone T, Isobe M, Ohshima T, Matsumura K, Oda M, Watanabe K.

Drug Metab Pharmacokinet. 2006 Apr;21(2):147-55.

21.

Stimulatory effects of testosterone and progesterone on the NADH- and NADPH-dependent oxidation of 7beta-hydroxy-delta8-tetrahydrocannabinol to 7-oxo-delta8-tetrahydrocannabinol in monkey liver microsomes.

Funahashi T, Tanaka Y, Yamaori S, Kimura T, Matsunaga T, Ohmori S, Kageyama T, Yamamoto I, Watanabe K.

Drug Metab Pharmacokinet. 2005 Oct;20(5):358-67.

22.
23.

Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5 and CYP3A7: lack of co-regulation of the expression of CYP3A in Japanese livers.

Yamaori S, Yamazaki H, Iwano S, Kiyotani K, Matsumura K, Saito T, Parkinson A, Nakagawa K, Kamataki T.

Xenobiotica. 2005 Jan;35(1):69-83.

PMID:
15788369
24.

Efficient immobilization of enzymes on microchannel surface through His-tag and application for microreactor.

Miyazaki M, Kaneno J, Yamaori S, Honda T, Briones MP, Uehara M, Arima K, Kanno K, Yamashita K, Yamaguchi Y, Nakamura H, Yonezawa H, Fujii M, Maeda H.

Protein Pept Lett. 2005 Feb;12(2):207-10.

PMID:
15723648
25.

CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects.

Yamaori S, Yamazaki H, Iwano S, Kiyotani K, Matsumura K, Honda G, Nakagawa K, Ishizaki T, Kamataki T.

Drug Metab Pharmacokinet. 2004 Apr;19(2):120-9.

26.

Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7.

Yamaori S, Yamazaki H, Suzuki A, Yamada A, Tani H, Kamidate T, Fujita Ki, Kamataki T.

Biochem Pharmacol. 2003 Dec 15;66(12):2333-40.

PMID:
14637191

Supplemental Content

Loading ...
Support Center